Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 681.78

+1.0%

Nov 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	12/7/2019 6:20:16 PM
	of 3557

RE: OT, AD XBIT sold bermekimab (at P2) to Janssen, for $1.3B (assuming all clinical MS) + $$$ for (initial) drug requirement manufacturing and service. finance.yahoo.com Open label, no placebo arm, P2 AD data : clinicaltrials.gov does not point to excesively potent Abs (even at 400 mg dose), Abs is active nonetheless, ..so...???? This is bit strange deal, as J&J take full control of bermekimab, and block XBIT to develop follow-on IL1a Abs for dermatology indications. So, what is life-time value of the development stage anti-IL1a Abs (drug)? XBIT think it is less than $1.3B (for them), and J&J think it is more. At the same time, is Janssen blocked to develop bermekimab outside dermatology? Bit's me!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next